```html

Yaws‑Associated Osteitis

Overview

Yaws‑associated osteitis is a chronic bone inflammation that develops after infection with Treponema pallidum* pertenue, the bacterium that causes yaws. Unlike the acute skin lesions of early yaws, osteitis appears months to years later and can lead to debilitating pain, deformities, and reduced mobility.

• Who it affects: Primarily children aged 5‑15 years living in low‑resource, tropical regions where yaws is endemic.
• Geographic distribution: Most cases are reported in West Africa, Southeast Asia, the Pacific Islands, and parts of South America. The World Health Organization (WHO) estimates that ~84 million people live in areas at risk for yaws, with approximately 10‑15 % of untreated cases progressing to osteitis.<sup>[1] WHO, 2022</sup>
• Prevalence: In hyper‑endemic communities, up to 30 % of children with a history of yaws develop bone involvement.<sup>[2] CDC, 2023</sup>

Symptoms

The presentation of yaws‑associated osteitis can be variable, but the most common features include:

Local bone pain

• Deep, aching pain that worsens with weight‑bearing or movement.
• Often described as “bone‑knocking” pain, especially in the tibia, femur, radius, and ulna.

Swelling and tenderness

• Localized swelling over the affected bone; may be fluctuant if a sub‑periosteal abscess forms.
• Warmth and erythema can be present in the acute phase.

Joint involvement

• Secondary arthritis may occur when the periosteum extends to adjacent joints, leading to stiffness and reduced range of motion.

Deformities

• Chronic inflammation can cause bowing of long bones (genu varum or valgum), shortening of limbs, and “saddle‑nose” deformity of the nasal bridge.

Systemic signs

• Low‑grade fever, fatigue, and malaise may accompany active inflammation.
• Weight loss is uncommon but can appear in severe, untreated disease.

Causes and Risk Factors

Etiology

Yaws is a non‑venereal treponemal disease transmitted through direct skin‑to‑skin contact with infectious lesions. After the primary cutaneous stage, the bacteria can disseminate hematogenously and seed the periosteum, leading to chronic osteitis.

Risk Factors

• Age: Children 5‑15 years have the highest exposure through play and close contact.
• Living conditions: Overcrowded, rural villages with limited access to sanitation and clean water.
• Co‑existing skin lesions: Untreated primary yaws lesions dramatically increase the risk of systemic spread.
• Immunocompromise: Malnutrition or HIV infection can impair clearance of the treponeme.
• Geographic isolation: Areas lacking routine mass‑drug administration (MDA) programs for yaws.

Diagnosis

Clinical assessment

Physicians rely on a combination of history (previous yaws infection or exposure) and physical examination (localized bone tenderness, swelling, and any residual skin lesions).

Laboratory tests

• Serologic testing: Rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) tests are non‑treponemal; they become positive in active infection. Treponemal tests (e.g., TPPA, FTA‑ABS) remain positive for life and confirm exposure.
• PCR: Real‑time PCR on a bone‑biopsy sample or ulcer swab can detect T. pallidum pertenue DNA, though this is rarely available in endemic settings.

Imaging studies

• X‑ray: Shows periosteal new bone formation, “onion‑skin” layering, and cortical thickening. Classic in tibia and femur.
• Ultrasound: Useful for detecting sub‑periosteal fluid collections in children.
• MRI: Provides detailed evaluation of marrow edema, soft‑tissue involvement, and early changes before radiographic findings appear.

Differential diagnosis

Conditions that mimic yaws‑associated osteitis include osteomyelitis (bacterial), tuberculous osteitis, sickle‑cell bone crises, and benign growths such as osteoid osteoma. A thorough travel/social history helps narrow the diagnosis.

Treatment Options

Antibiotic therapy

The cornerstone of treatment is a single‑dose oral azithromycin (30 mg/kg, max 2 g). Azithromycin has shown >95 % cure rates for both early and late yaws and is recommended by WHO for mass‑drug administration programs.

• Alternative: Benzathine penicillin G 2.4 MU intramuscularly (single dose) for patients with azithromycin allergy.
• For persistent osteitis after initial therapy, a 10‑day course of oral doxycycline (100 mg BID) or amoxicillin (500 mg TID) may be considered, but data are limited.<sup>[3] WHO, 2020</sup>

Supportive care

• Pain control: NSAIDs (ibuprofen 10 mg/kg q6‑8h) or acetaminophen as first‑line; consider short courses of opioids for severe pain under medical supervision.
• Immobilization: Splinting or a lightweight brace reduces stress on the inflamed bone during the acute phase (usually 2‑4 weeks).

Surgical intervention

Rarely needed, but indicated when:

• Sub‑periosteal abscesses fail to resolve with antibiotics.
• Severe deformities cause functional impairment; corrective osteotomy may be performed after infection control.

Rehabilitation & lifestyle

• Physical therapy to maintain joint range of motion and strengthen surrounding musculature.
• Gradual return to activity once pain subsides; avoid high‑impact sports for 6‑8 weeks.

Living with Yaws‑Associated Osteitis

Daily management tips

1. Medication adherence: Complete the full course of antibiotics even if symptoms improve.
2. Pain monitoring: Keep a diary of pain intensity and triggers; adjust NSAID dosing under physician guidance.
3. Skin care: Treat any residual yaws lesions promptly to prevent reinfection.
4. Nutrition: A balanced diet rich in calcium and vitamin D supports bone healing. Supplements may be needed in malnourished children.
5. Footwear: Use well‑fitted, supportive shoes to reduce stress on the tibia and femur.
6. School attendance: Coordinate with teachers for short rest periods during acute pain spikes.

Psychosocial aspects

Chronic pain and visible deformities can affect self‑esteem. Community health workers should address stigma and connect families with counseling services where available.

Prevention

• Mass‑drug administration (MDA): WHO recommends biannual azithromycin MDA in endemic districts to interrupt transmission.
• Early treatment of primary lesions: Prompt antibiotic therapy within 2 weeks of skin lesion onset prevents systemic spread.
• Hygiene education: Teach children to cover skin ulcers and avoid sharing towels or clothing that contacts lesions.
• Surveillance: Regular community skin‑checks by trained health volunteers help identify new cases early.
• Vaccination research: No licensed vaccine exists yet, but several phase‑II trials are ongoing (e.g., TpN47 protein vaccine).<sup>[4] NIH, 2023</sup>

Complications

If left untreated, yaws‑associated osteitis can lead to:

• Permanent bone deformities (bowing, shortening) requiring orthopedic surgery.
• Secondary bacterial superinfection of ulcerated skin or bone (osteomyelitis).
• Functional impairment—difficulty walking, climbing stairs, or performing daily activities.
• Growth retardation in children due to chronic inflammation.
• Psychological sequelae: social isolation, depression, or anxiety.

When to Seek Emergency Care

References

1. World Health Organization. Yaws: Guidelines for Global Elimination. Geneva: WHO; 2022.
2. Centers for Disease Control and Prevention. Yaws – Epidemiology & Statistics. Updated 2023. https://www.cdc.gov/yaws
3. World Health Organization. Azithromycin Mass Drug Administration for Yaws. 2020.
4. National Institutes of Health. ClinicalTrials.gov: Treponema pallidum vaccine studies. Accessed 2023.
5. Mayo Clinic. Osteitis – Symptoms and causes. Updated 2024. https://www.mayoclinic.org

``` *Word count: approximately 1,380 words.*